Clinical meaning
The auditory system begins developing early in embryonic life, with the cochlea reaching structural maturity by approximately 20 weeks of gestation and functional maturity by 28-30 weeks. By the third trimester, the fetus can respond to sound, demonstrating heart rate changes and motor responses to auditory stimuli. At birth, the peripheral auditory system (outer ear, middle ear, cochlea, and auditory nerve) is structurally mature, although the central auditory pathways (brainstem to auditory cortex) continue to mature throughout the first two years of life, driven by auditory stimulation. Sound travels through the external auditory canal to the tympanic membrane, which vibrates in response to pressure waves. These vibrations are transmitted through the middle ear ossicles (malleus, incus, stapes) to the oval window of the cochlea. Within the cochlea, fluid waves displace the basilar membrane, which activates the inner hair cells (approximately 3,500 cells arranged in a single row). Inner hair cells are the primary sensory receptors that convert mechanical energy into electrical signals transmitted via the cochlear nerve (CN VIII) to the brainstem. The outer hair cells (approximately 12,000 cells in three rows) function as cochlear amplifiers, enhancing the sensitivity and frequency selectivity of the inner hair cells. Outer hair cells contract and expand in response to sound stimulation, a process called electromotility; this active mechanical process produces sounds called otoacoustic emissions (OAEs) that can be measured in the ear canal and serve as the basis for OAE hearing screening. Hearing loss in neonates is classified by location: conductive hearing loss results from problems in the outer or middle ear (cerumen impaction, otitis media with effusion, ossicular malformation); sensorineural hearing loss results from damage to the cochlear hair cells or auditory nerve (genetic mutations, ototoxic medications, congenital infections, hyperbilirubinemia); and auditory neuropathy spectrum disorder results from impaired neural processing despite functioning hair cells. The incidence of congenital hearing loss is approximately 1-3 per 1,000 live births, making it one of the most common congenital conditions. Without screening, the average age of hearing loss identification was historically 24-30 months, well past the critical period for language development (birth to 3 years). Universal newborn hearing screening (UNHS) programs aim to screen by 1 month of age, confirm hearing loss by 3 months, and initiate intervention by 6 months (the 1-3-6 guideline). Two primary screening technologies are used. Otoacoustic emissions (OAE) testing measures sounds produced by the outer hair cells in response to auditory stimulation; a small probe placed in the ear canal delivers clicks or tones and a sensitive microphone records the emissions. OAE testing is quick (1-5 minutes per ear), non-invasive, and does not require sedation, but it can only detect hearing loss originating in the cochlea (sensorineural) and does not detect auditory neuropathy. Auditory brainstem response (ABR) testing measures electrical activity in the auditory nerve and brainstem in response to sound stimuli delivered through earphones. Electrodes placed on the infant's scalp record the neural waveforms. ABR is more comprehensive, detecting both cochlear and neural hearing loss, and is the gold standard confirmatory test for neonatal hearing loss. ABR testing takes longer (15-30 minutes per ear), requires the infant to be sleeping or sedated, and requires trained audiological interpretation. The practical nurse plays a key role in ensuring screening is completed before hospital discharge, educating parents about follow-up for referred (failed) screens, and monitoring developmental milestones related to hearing and language acquisition.